Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1696 AL 1710

Thalamic ¹²³I FP-CIT uptake in a patient with clinical diagnosis of Parkinson's disease and depression

Schillaci O, Chiaravalloti A, Pietro BD, Stefani A.

Hell J Nucl Med. 2012 Jan-Apr;15(1):74-5.

[Neurodegenerative diseases]

Takanashi M, Hattori N.

Nihon Rinsho. 2012 Jan;70(1):94-8.

[Emotions and amyotrophic lateral sclerosis: a psychopathological perspective]

Bungener C.

Geriatr Psychol Neuropsychiatr Vieil. 2012 Mar;10(1):57-64. doi: 10.1684/pnv.2012.0313.

Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression

McDermott CL, Gray SL.

Ann Pharmacother. 2012 Apr;46(4):599-605. doi: 10.1345/aph.1Q445. Epub 2012 Mar 13.

The effect of Alzheimer's disease and Parkinson's disease on olfaction: a meta-analysis

Rahayel S, Frasnelli J, Joubert S.

Behav Brain Res. 2012 May 16;231(1):60-74. doi: 10.1016/j.bbr.2012.02.047. Epub 2012 Mar 5.

Prevalence of sleep disturbances in mild cognitive impairment and dementing disorders: a multicenter Italian clinical cross-sectional study on 431 patients

Guarnieri B, Adorni F, Musicco M, Appollonio I, Bonanni E, Caffarra P, Caltagirone C, Cerroni G, Concari L, Cosentino FI, Ferrara S, Fermi S, Ferri R, Gelosa G, Lombardi G, Mazzei D, Mearelli S, Morrone E, Murri L, Nobili FM, Passero S, Perri R, Rocchi R, Sucapane P, Tognoni G, Zabberoni S, Sorbi S.

Dement Geriatr Cogn Disord. 2012;33(1):50-8. doi: 10.1159/000335363. Epub 2012 Mar 8.

Magnetic resonance imaging markers for early diagnosis of Parkinson's disease

Marino S, Ciurleo R, Di Lorenzo G, Barresi M, De Salvo S, Giacoppo S, Bramanti A, Lanzafame P, Bramanti P.

Neural Regen Res. 2012 Mar 15;7(8):611-9. doi: 10.3969/j.issn.1673-5374.2012.08.009.

Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease

Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P.

Exp Neurol. 2012 Jun;235(2):528-38. doi: 10.1016/j.expneurol.2012.02.017. Epub 2012 Mar 7.

Medication improves balance and complex gait performance in Parkinson disease

McNeely ME, Duncan RP, Earhart GM.

Gait Posture. 2012 May;36(1):144-8. doi: 10.1016/j.gaitpost.2012.02.009. Epub 2012 Mar 13.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.

Discovery of MAO-B inhibitors - present status and future directions part I: oxygen heterocycles and analogs

Helguera AM, Perez-Machado G, Cordeiro MN, Borges F.

Mini Rev Med Chem. 2012 Sep 1;12(10):907-19. doi: 10.2174/138955712802762301.

Nanopore analysis: An emerging technique for studying the folding and misfolding of proteins

Madampage C, Tavassoly O, Christensen C, Kumari M, Lee JS.

Prion. 2012 Apr-Jun;6(2):116-23. doi: 10.4161/pri.18665. Epub 2012 Apr 1.

Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial

Nagata K, Yokoyama E, Yamazaki T, Takano D, Maeda T, Takahashi S, Terayama Y.

Phytomedicine. 2012 Apr 15;19(6):524-8. doi: 10.1016/j.phymed.2012.02.008. Epub 2012 Mar 13.

Restless legs syndrome responsive to rasagiline treatment: a case report

Babacan-Yildiz G, Gursoy E, Kolukisa M, Celebi A.

Clin Neuropharmacol. 2012 Mar-Apr;35(2):88-9. doi: 10.1097/WNF.0b013e31824c1c3f.

Amantadine-induced myoclonus in a patient with progressive supranuclear palsy

Yarnall AJ, Burn DJ.

Age Ageing. 2012 Sep;41(5):695-6. doi: 10.1093/ageing/afs043. Epub 2012 Mar 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias